<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="29835">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02718300</url>
  </required_header>
  <id_info>
    <org_study_id>INCB 50465-201</org_study_id>
    <nct_id>NCT02718300</nct_id>
  </id_info>
  <brief_title>A Study of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis</brief_title>
  <official_title>A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Incyte Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Incyte Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, tolerability, and efficacy of the
      combination of INCB050465 and ruxolitinib in subjects with myelofibrosis.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Anticipated">September 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part 1: Number of Participants With Dose Limiting Toxicities (DLTs)</measure>
    <time_frame>Baseline to Day 28</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Change From Baseline in Spleen Volume at Week 12 as measured by MRI or CT scan</measure>
    <time_frame>Baseline to Week 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with adverse events (AEs) and changes in vital signs, ECGs, and laboratory parameters</measure>
    <time_frame>Screening through up to 30 days after last dose of study drug, up to 25 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in total symptom score as measured by patient-reported myelofibrosis symptoms</measure>
    <time_frame>Baseline through Week 12 or Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Spleen Volume at Week 24 as measured by MRI or CT scan</measure>
    <time_frame>Baseline to Week 24</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">78</enrollment>
  <condition>Myelofibrosis</condition>
  <arm_group>
    <arm_group_label>Part 1: Ruxolitinib + INCB050465</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Initial cohort dose of INCB050465 added to existing stable regimen of ruxolitinib, with subsequent cohort escalations based on protocol-specific criteria.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: Ruxolitinib + INCB050465</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part 2 will compare 2 doses of INCB050465</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>INCB050465</intervention_name>
    <description>Up to 3 oral once a day (QD) doses of INCB050465.</description>
    <arm_group_label>Part 1: Ruxolitinib + INCB050465</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>INCB050465</intervention_name>
    <description>Two recommended oral QD doses of INCB050465.</description>
    <arm_group_label>Part 2: Ruxolitinib + INCB050465</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ruxolitinib</intervention_name>
    <description>The dose of ruxolitinib will be that which the subjects had been taking for at least 8 weeks before the first dose of INCB050465.</description>
    <arm_group_label>Part 1: Ruxolitinib + INCB050465</arm_group_label>
    <arm_group_label>Part 2: Ruxolitinib + INCB050465</arm_group_label>
    <other_name>Jakafi®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of primary myelofibrosis, post-polycythemia vera myelofibrosis, or
             post-essential thrombocythemia myelofibrosis

          -  Palpable spleen of &gt; 10 cm below the left subcostal margin on physical examination at
             the screening visit OR

          -  Palpable splenomegaly of 5 to 10 cm below left subcostal margin on physical exam AND
             active symptoms of MF at the screening visit as demonstrated by presence of 1 symptom
             score ≥ 5 or 2 symptom scores ≥ 3 using the Screening Symptom Form

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2

        Exclusion Criteria:

          -  Use of experimental drug therapy for myelofibrosis, or any other standard drug (eg,
             danazol, hydroxyurea, etc) with the exception of ruxolitinib within 6 months of
             starting study (combination) therapy and/or lack of recovery from all toxicities from
             previous therapy (except ruxolitinib) to Grade 1 or better

          -  Inability to swallow food or any condition of the upper gastrointestinal tract that
             precludes administration of oral medications

          -  Unwillingness to be transfused with blood components

          -  Recent history of inadequate bone marrow reserve as demonstrated by the following:

               -  Platelet count &lt; 50 × 10^9/L in the 4 weeks before screening or platelet
                  transfusion(s) within 8 weeks before screening

               -  Absolute neutrophil count levels &lt; 0.5 × 10^9/L in the 4 weeks before screening

               -  Subjects with peripheral blood blast count of &gt; 10% at the screening or baseline
                  hematology assessments

               -  Subjects who are not willing to receive red blood cell (RBC) transfusions to
                  treat low hemoglobin levels

          -  Inadequate liver function at screening and baseline visits as demonstrated by the
             following:

               -  Direct bilirubin ≥ 2.0 × the upper limit of laboratory normal (ULN). (NOTE:
                  direct bilirubin will only be determined if total bilirubin is ≥ 2.0 × ULN)

               -  alanine aminotransferase (ALT) or aspartate aminotransferase (AST) &gt; 2.5 × ULN

          -  Inadequate renal function at screening and baseline visits as demonstrated by
             creatinine clearance &lt; 50 mL/min or glomerular filtration rate &lt; 50 mL/min/1.73 m^2
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Albert Assad, MD</last_name>
    <role>Study Director</role>
    <affiliation>Incyte Corporation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Incyte Corporation Call Center</last_name>
    <phone>1.855.463.3463</phone>
  </overall_contact>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Ames</city>
        <state>Iowa</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Westwood</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Kerrville</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Colchester</city>
        <state>Vermont</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <lastchanged_date>September 29, 2016</lastchanged_date>
  <firstreceived_date>March 21, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Primary myelofibrosis (PMF)</keyword>
  <keyword>post-polycythemia vera myelofibrosis (PPV-MF)</keyword>
  <keyword>post-essential thrombocythemia myelofibrosis (PET-MF)</keyword>
  <keyword>myeloproliferative neoplasms (MPNs)</keyword>
  <keyword>phosphoinositide 3-kinase (PI3K) inhibitor</keyword>
  <keyword>Janus kinase (JAK) inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Primary Myelofibrosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
